Market news

MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.

Medifast (MED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Parsa Kiai, Director, on August 26, 2026, executed a purchase for 43,150 shares in Medifast (MED) fo

BALTIMORE, August 27, 2026--Medifast, Inc. (NYSE: MED) has announced the launch of the Medifast Metabolic Health Institute, established to advance metabolic health through rigorous research and credible, evidence-based education.

MED's Trilivy launch marks a major metabolic-health shift, backed by a 10-year roadmap and growing GLP-1 market focus.

Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp decline in active earning coaches.

MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.

Medifast’s second quarter was marked by stabilization in key business metrics despite continued pressure from declining coach numbers and shifting industry trends. The company’s revenue and earnings surpassed Wall Street expectations, contributing to a strong positive market reaction. Management credited improved coach productivity—up for the third consecutive quarter—and the early impact of its new consumer brand, Trilivy, as key drivers of sequential stabilization. CEO Nick Johnson highlighted

Coach count plummeted 48.7%, yet management targets profitability by Q4 2026.

Detailed price information for Medifast Inc (MED-N) from The Globe and Mail including charting and trades.

Detailed price information for Medifast Inc (MED-N) from The Globe and Mail including charting and trades.

Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.

Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.

Detailed price information for Medifast Inc (MED-N) from The Globe and Mail including charting and trades.

Shares of wellness company Medifast (NYSE:MED) jumped 37.5% in the afternoon session after the company reported second-quarter results that surpassed expectations and provided an optimistic full-year earnings forecast. The wellness company posted a loss of $0.28 per share, which was significantly narrower than the $0.65 loss that analysts had anticipated. Revenue of $76.38 million also beat estimates, though it marked a 27.6% decline from the previous year. The key driver for the stock's jump ap

Why Medifast (MED) Stock Is Trading Up Today

MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.

Moby summary of Medifast, Inc.'s Q2 2026 earnings call

Medifast Inc (MED) navigates a 27.6% revenue drop while boosting coach productivity 41% and launching its Trilivy brand to target metabolic health and return to profitability by Q4 2026.

Medifast (NYSE:MED) reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or

Medifast (MED) delivered earnings and revenue surprises of +58.21% and +1.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Wellness company Medifast (NYSE:MED) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 27.6% year on year to $76.38 million. On top of that, next quarter’s revenue guidance ($70 million at the midpoint) was surprisingly good and 3.4% above what analysts were expecting. Its GAAP loss of $0.28 per share was 56.9% above analysts’ consensus estimates.

Gainers Medifast (NYSE:MED) stock increased by 10.7% to $10.78 during Monday's after-market session. The market value of their outstanding shares is at $108.0 million. The company's, Q2 earnings came out today.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Wellness company Medifast (NYSE:MED) will be reporting results this Monday after market hours. Here’s what you need to know.

Earnings To Watch: Medifast (MED) Reports Q2 Results Tomorrow

MED's Q2 results are likely to face continued pressure from GLP-1 adoption and a smaller coach base, while productivity gains and cost actions may have helped offset some challenges.

Medifast (MED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BALTIMORE, July 20, 2026--Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, will announce financial results for the quarter ended June 30, 2026 on Monday, August 3, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Nick Johnson, Chief Executive Officer, and Jim Maloney, Chief Financial Officer.

Medifast's Trilivy expands beyond weight management with metabolic health support, personalized coaching and a structured three-phase journey.

BALTIMORE, July 17, 2026--Medifast, Inc. (NYSE: MED) today announced the launch of Trilivy, a comprehensive metabolic health system uniquely designed to support healthy lifestyle change. The launch also introduces newly formulated meal replacements, including the Trilivy Reset Fueling line enhanced with MetaVantage Technology™, a platform of proprietary ingredient formulas intended to optimize metabolism by unlocking key metabolic pathways. The launch of Trilivy marks a major corporate transform

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Medifast (NYSE:MED) and the best and worst performers in the personal care industry.

Detailed price information for Medifast Inc (MED-N) from The Globe and Mail including charting and trades.